| Name | Title | Contact Details |
|---|
Mesa Plms Retirement Cmnty is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
QuVa Pharma, Inc. is a newly-formed national platform for sterile compounding pharmacy services led by two experienced industry executives that has received a majority equity commitment from Bain Capital Private Equity to support the company’s creation and expansion plans. As part of its formation, QuVa Pharma has acquired the assets of the compounding services division of a company leader in the field of parenteral and management services, including its state-of-the-art 503B manufacturing facility in Sugar Land, Texas.
Medical DecisionPoint is a Montvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FORTE is a female founded and led technology company. Launched by Lauren Foundos in 2015, FORTË`s while label streaming platform helps boutique fitness studios, big box gyms and health clubs create premium live and on-demand fitness experiences for members. The FORTË solution is proprietary, turn-key and all inclusive. The company provides hardware and software, and facilitates the entire installation process. By removing complexities associated with production, FORTË`s fully-automated streaming solution allows fitness operators to focus on what they do best - create world-class content and deliver it to members wherever they are.
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.